Compare AstraZeneca plc (AZN) vs Raymond James Financial, Inc. (RJF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Raymond James Financial, Inc. — how do they compare? AstraZeneca plc trades at $158.44 (market cap $248.14B), while Raymond James Financial, Inc. trades at $180.94 (market cap $34.63B). The key difference: AstraZeneca plc is far larger — about 7.2× Raymond James Financial, Inc.'s market cap, and AstraZeneca plc pays the higher dividend (2.01%). Which is the better fit depends on your goals.
| AZN | RJF | |
|---|---|---|
Market Cap | $248.14B | $34.63B |
Sector | Health | Financials |
52-Week High | $209.48 | $180.55 |
52-Week Low | $147.06 | $140.89 |
Enterprise Value | $275.41B | — |
Dividend Yield | 2.01% | 1.2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $158.48, down 2.12% amid bearish technical signals and merger speculation. The stock shows strong fundamentals with revenue growth from $54.1B in 2024 to $58.7B in 2025 and net income reaching $10.2B. Recent earnings beats and a 47.5% analyst buy rating contrast with technical indicators showing oversold conditions near key support at $155.
Investment outlook remains positive based on earnings momentum and valuation metrics (P/E 23.76), though risks include potential merger integration challenges and ongoing legal investigations. The company's robust cash flow generation and dividend payments provide shareholder value support despite near-term volatility.
Raymond James Financial (RJF) trades at $180.34, up 0.7% for the day, with a bullish technical signal and strong earnings beats in recent quarters. The stock shows robust revenue growth, with 2025 revenue at $13.84B and net income of $2.14B, supported by a P/E of 15.69 and net margin of 15.37%. Recent news highlights record Q3 2026 results and a golden cross formation, indicating positive momentum.
Outlook is positive due to consistent earnings outperformance and analyst buy ratings, but risks include volatile cash flows from investing activities and reliance on capital markets strength. The consensus price target of $183.75 suggests modest upside, with institutional interest shown by CalPERS' recent share acquisition.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Raymond James Financial, Inc.
Raymond James Financial is a financial holding company whose major operations include wealth management, investment banking, asset management, and commercial banking. The company has more than 14,000 employees and supports more than 5,000 independent contractor financial advisors across the United States, Canada, and the United Kingdom. Approximately 90% of the company's revenue is from the U.S. and 70% is from the company's wealth-management segment.
Read more on RJF →
